|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Chemotherapy delay due to neutropenia was higher in patients who received granulocyte-colony stimulating factor on day 1.
|
31042138 |
2020 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
We evaluated a retrospective cohort of 228 adult lung transplant recipients between 2008 and 2013 to assess the association of neutropenia and granulocyte colony-stimulating factor (GCSF) treatment with outcomes.
|
31452317 |
2020 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
He responded well to filgrastim (Neupogen) and blood transfusions, so a drug-related cause of neutropenia has been suspected.
|
31142911 |
2020 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Chemotherapy delays due to neutropenia and leukopenia were significantly decreased among patients that received G-CSF (OR 0.098, 95% CI 0.06-0.15 and OR 0.32, 95% CI 0.18-0.58, respectively).<b>Discussion:</b> In conclusion, G-CSF support reduces neutropenic events and permits increased relative dose intensity, which is essential for improved survival outcomes.
|
31583943 |
2020 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The use of granulocyte colony-stimulating factor can be beneficial to shorten the duration of neutropenia.
|
31842164 |
2020 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Granulocyte colony-stimulating factor (G-CSF) is widely used for prophylaxis and treatment of neutropenia in cancer patients and also for peripheral blood stem cells (PBSC) mobilization.
|
31003920 |
2020 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Treatment with G-CSF could eventually be stopped, and the neutropenia, ultimately transient in nature, completely resolved.
|
30633375 |
2019 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
We conducted this review of neutropenia in BTHS to aid in the diagnosis of this disease, and to improve understanding of both the consequences of neutropenia and the benefits of treatment with granulocyte colony-stimulating factor (G-CSF).
|
30451719 |
2019 |
|
Leukopenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Patients with WHIM syndrome are often treated with granulocyte colony-stimulating factor (G-CSF), which can increase neutrophil counts but does not affect cytopenias other than neutropenia.
|
30625055 |
2019 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Twenty-eight (19%) patients were treated with peg-filgrastim as primary prophylaxis, while 74 (64%) received filgrastim "on demand" due to neutropenia.
|
31152919 |
2019 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Granulocyte-colony stimulating factor (G-CSF, 10 μg/kg/day, subcutaneously) was administered from the onset of neutropenia to the final day of collection.
|
30642286 |
2019 |
|
Leukopenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
G4 neutropenia occurred in 11 patients (28 of 33 cycles) in the filgrastim arm and 9 patients (18 of 33 cycles) in the pegfilgrastim arm (P = 0.476).
|
31728715 |
2019 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Patients received subcutaneous filgrastim as part of the prophylaxis regimen for neutropenia.
|
31623097 |
2019 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Granulocyte colony-stimulating factor (G-CSF) is the standard-of-care therapy for chemotherapy-associated neutropenia in patients with malignancies.
|
30875590 |
2019 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Granulocyte colony-stimulating factor (G-CSF) is commonly administered to prevent serious complications caused by chemotherapy-induced neutropenia; however, several cases of arteritis following the administration of G-CSF have been reported.
|
31090035 |
2019 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Low-dose G-CSF administered to childbearing women during pregnancy could be proposed to prevent neutropenia in newborns.
|
30900095 |
2019 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Sandoz biosimilar filgrastim was approved based on Phase III confirmatory studies conducted in patients with breast cancer experiencing chemotherapy-induced neutropenia, with other indications granted based on extrapolation.
|
31405784 |
2019 |
|
Leukopenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Bone marrow progenitor cell colony-forming unit (CFU) count, serum cytokine levels, and peripheral leukocyte count after HIPEC and IP chemotherapy were compared.<b>Results:</b> Peripheral neutrophil count, cytokine (G-CSF and CXCL1/KC) levels, and bone marrow progenitor cell CFU count were significantly higher after HIPEC than after IP chemotherapy.<b>Conclusions:</b> Hyperthermia increased the serum neutrophil-recruiting cytokine levels and reduced the magnitude of chemotherapy-induced neutropenia.
|
31818168 |
2019 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Exposure-safety analyses supported the recommended brentuximab vedotin starting dose (1.2 mg/kg every 2 weeks), and effective management of peripheral neuropathy and neutropenia with dose modification/reduction and febrile neutropenia with granulocyte colony-stimulating factor primary prophylaxis.
|
31152605 |
2019 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The use of G-CSF improves patient survival and reduces the rate of neutropenia complications.
|
31798380 |
2019 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Granulocyte colony-stimulating factor (G-CSF) is a glycoprotein commonly used in the field of medicine to treat neutropenia.
|
30497339 |
2019 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
In phase III trials, once per cycle prophylaxis with mecapegfilgrastim was more effective than placebo in reducing the incidence of grade ≥ 3 neutropenia in cycle 1 in patients with advanced non-small cell lung cancer and was more effective than filgrastim at reducing the mean duration of grade ≥ 3 neutropenia in cycle 1 in patients with breast cancer.
|
31489570 |
2019 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Of note, risk factors have changed with the advent of hematopoietic cytokines (especially granulocyte colony-stimulating factor) in shortening the duration of neutropenia, as well as with the discovery of more targeted cancer treatments that do not result in cytotoxicity, although these are still the exception.
|
30856657 |
2019 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Current guidelines (GL) recommend neutropenia prophylaxis with G-CSF after chemotherapy (CTX) for patients with high (≥ 20%), or, if additional risk factors are present, intermediate (≥ 10-20%) risk of febrile neutropenia.
|
30374765 |
2019 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our study goal was to forecast the necessary dose of G-CSF by comparing day 8 neutropenia with putative changes within the neutrophil pool.
|
30998754 |
2019 |